BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16489049)

  • 21. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
    Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
    J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors.
    Lotem M; Zhao Y; Riley J; Hwu P; Morgan RA; Rosenberg SA; Parkhurst MR
    J Immunother; 2006; 29(6):616-27. PubMed ID: 17063124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
    Touloukian CE; Leitner WW; Topalian SL; Li YF; Robbins PF; Rosenberg SA; Restifo NP
    J Immunol; 2000 Apr; 164(7):3535-42. PubMed ID: 10725708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity.
    Abdel-Wahab Z; DeMatos P; Hester D; Dong XD; Seigler HF
    Cell Immunol; 1998 May; 186(1):63-74. PubMed ID: 9637766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-gamma mediates antigen trafficking to MHC class II-positive late endosomes of enterocytes.
    Büning J; Schmitz M; Repenning B; Ludwig D; Schmidt MA; Strobel S; Zimmer KP
    Eur J Immunol; 2005 Mar; 35(3):831-42. PubMed ID: 15688349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of human CD4+ T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences.
    Niazi KR; Ochoa MT; Sieling PA; Rooke NE; Peter AK; Mollahan P; Dickey M; Rabizadeh S; Rea TH; Modlin RL
    Immunology; 2007 Dec; 122(4):522-31. PubMed ID: 17635609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
    Parkhurst MR; DePan C; Riley JP; Rosenberg SA; Shu S
    J Immunol; 2003 May; 170(10):5317-25. PubMed ID: 12734382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing.
    Bellemare-Pelletier A; Tremblay J; Beaulieu S; Boulassel MR; Routy JP; Massie B; Lapointe R; Thibodeau J
    J Leukoc Biol; 2005 Jul; 78(1):95-105. PubMed ID: 15817706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3.
    Halder T; Pawelec G; Kirkin AF; Zeuthen J; Meyer HE; Kun L; Kalbacher H
    Cancer Res; 1997 Aug; 57(15):3238-44. PubMed ID: 9242455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.
    Robbins PF; El-Gamil M; Li YF; Fitzgerald EB; Kawakami Y; Rosenberg SA
    J Immunol; 1997 Jul; 159(1):303-8. PubMed ID: 9200467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melanoma cells present high levels of HLA-A2-tyrosinase in association with instability and aberrant intracellular processing of tyrosinase.
    Michaeli Y; Sinik K; Haus-Cohen M; Reiter Y
    Eur J Immunol; 2012 Apr; 42(4):842-50. PubMed ID: 22531911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
    Al-Batran SE; Rafiyan MR; Atmaca A; Neumann A; Karbach J; Bender A; Weidmann E; Altmannsberger HM; Knuth A; Jäger E
    Cancer Res; 2005 May; 65(9):3937-41. PubMed ID: 15867394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
    Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
    Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G
    Eur J Immunol; 1998 Apr; 28(4):1143-54. PubMed ID: 9565353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.
    Parkhurst MR; Riley JP; Robbins PF; Rosenberg SA
    J Immunother; 2004; 27(2):79-91. PubMed ID: 14770079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones.
    Sensi M; Pellegatta S; Vegetti C; Nicolini G; Parmiani G; Anichini A
    Tissue Antigens; 2002 Apr; 59(4):273-9. PubMed ID: 12135425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope.
    Kallinteris NL; Wu S; Lu X; Humphreys RE; von Hofe E; Xu M
    J Immunother; 2005; 28(4):352-8. PubMed ID: 16000953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.